Literature DB >> 29405162

Diagnosis and treatment of diffusible Penicillium marneffei in human immunodeficiency virus-negative patients: A challenge for the physician.

Xiao-Hua Chi1, Yao-Ming Xue2, Quan-Shi Wang1, Gui-Ping Li1, Hong-Sheng Zhou3, Yong-Shuai Qi1.   

Abstract

Penicillium marneffei infection in human immunodeficiency virus (HIV)-negative patients is addressed far less often. In this article, a small cohort of HIV-negative patients who disseminated P. marneffei infection was included. Sites of infection were found from blood culture, as subcutaneous nodules, or from lymph node biopsy. Fever, rash, swollen lymph nodes, anaemia and weight loss were common characteristics in most infected patients. The signs and symptoms are diverse and create challenges for accurate diagnosis. This paper will assist our understanding of this disease and contribute to an appropriate regime of therapy, thus improving the health of P. marneffei-positive patients.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29405162     DOI: 10.4103/ijmm.IJMM_15_418

Source DB:  PubMed          Journal:  Indian J Med Microbiol        ISSN: 0255-0857            Impact factor:   0.985


  3 in total

1.  Characteristics and Prognosis of Talaromyces marneffei Infection in Non-HIV-Infected Children in Southern China.

Authors:  Jing Guo; Bing-Kun Li; Tian-Min Li; Fang-Lin Wei; Yu-Jiao Fu; Yan-Qing Zheng; Kai-Su Pan; Chun-Yang Huang; Cun-Wei Cao
Journal:  Mycopathologia       Date:  2019-08-31       Impact factor: 2.574

2.  Talaromyces marneffei infection associated with bronchiolitis obliterans in an HIV-negative child: a case report.

Authors:  Lin Lin; Huifeng Fan; Dongwei Zhang; Gen Lu
Journal:  BMC Infect Dis       Date:  2022-05-16       Impact factor: 3.667

3.  MALDI-TOF MS-Based Clustering and Antifungal Susceptibility Tests of Talaromyces marneffei Isolates from Fujian and Guangxi (China).

Authors:  Lili Fang; Minxue Liu; Chunlan Huang; Jian Guo; Xiaobo Ma; Yanqing Zheng; Wenjuan Wu; Jiangshan Huang; Heping Xu
Journal:  Infect Drug Resist       Date:  2022-07-01       Impact factor: 4.177

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.